Results 181 to 190 of about 175,080 (313)

Medicine for the Material World

open access: yesArchaeometry, EarlyView.
ABSTRACT It is clear that many of the inorganic materials of antiquity have been used both as medicines for human ills and also as agents in technological processes. This paper speculates that there might have been a stronger link between these two functions in the past, based on the concept of “active agents”—materials that are efficacious at curing ...
A. M. Pollard
wiley   +1 more source

Integration of epigenetics into ecotoxicology: insights and fundamental research needs

open access: yesBiological Reviews, EarlyView.
ABSTRACT Epigenetics refers to heritable changes in genome function that occur without direct alterations to the DNA sequence. A multitude of environmental contaminants can influence the epigenetic marks of a genome. Changes of epigenetic marks including DNA methylation, histone modifications, and non‐coding RNAs can induce alterations at the gene ...
Albano Pinto   +3 more
wiley   +1 more source

Arsenic in Drinking Water and Prostate Cancer: A Population-Based Case-Control Study in Northern Chile. [PDF]

open access: yesCancer Epidemiol Biomarkers Prev
Schwalb ME   +4 more
europepmc   +1 more source

FB23‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF/ERCC1 Complex

open access: yesCancer Science, EarlyView.
FB23‐2 potentiates cisplatin's antitumor efficacy in head and neck squamous cell carcinoma by disrupting XPF/ERCC1 complex assembly and nuclear translocation, thereby suppressing DNA damage repair machinery and amplifying platinum‐induced tumor cell death.
Yaoqi Jiang   +7 more
wiley   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

open access: yesCancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase   +14 more
wiley   +1 more source

Arsen [PDF]

open access: yesFresenius' Zeitschrift für analytische Chemie, 1919
S. Goy, null Forster, null Riechelmann
openaire   +1 more source

Home - About - Disclaimer - Privacy